Format

Send to

Choose Destination
J Invest Dermatol. 2015 Aug;135(8):1946-1953. doi: 10.1038/jid.2015.144. Epub 2015 Mar 24.

IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies.

Author information

1
Department of Dermatology, Oregon Medical Research Center, Portland, Oregon, USA. Electronic address: ablauvelt@oregonmedicalresearch.com.
2
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
3
Department of Dermatology, Innovaderm Research, Montreal, Quebec, Canada.

Abstract

Biologics that neutralize specific cytokines have improved outcomes for several immune-mediated disorders but may also increase risks for particular side effects. This article postulates potential immunologic consequences of inhibiting components of the IL-23/T-helper cell 17 pathway-the target of next-generation biologics for treating psoriasis-based on clinical phenotypes of inherent or acquired deficiencies in this pathway. Generally, downstream deficiencies (e.g., IL-17A, IL-17F) are associated with fewer disorders compared with upstream deficiencies, suggesting that selectively blocking downstream targets may result in a narrower range of side effects. However, safety of these specific inhibitions must be established in long-term studies.

PMID:
25972190
PMCID:
PMC4580732
DOI:
10.1038/jid.2015.144
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center